James N. Lowder

A clinical trial of anti-idiotype therapy for B cell malignancy

TC Meeker, James N. Lowder, DG Maloney et al. · Blood · 1985 · 423 citations

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Jean‐Pierre J. Issa, Gail J. Roboz, David A. Rizzieri et al. · The Lancet Oncology · 2015 · 280 citations · Full text

Hematological Malignancy, Dose-escalation Phase 1, Oncology +9

Emergence of Idiotype Variants during Treatment of B-Cell Lymphoma with Anti-Idiotype Antibodies

T C Meeker, James N. Lowder, Michael L. Cleary et al. · New England Journal of Medicine · 1985 · 254 citations

A Phase I Study of Visilizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Severe Steroid-Refractory Ulcerative Colitis

Scott E. Plevy, Bruce Salzberg, Gert Van Assche et al. · Gastroenterology · 2007 · 144 citations · Full text

Inflammation, Anti-inflammatory, Autoimmune Disease +7

Bacteremias and Fungemias in Oncologic Patients With Central Venous Catheters

James N. Lowder · Archives of Internal Medicine · 1982 · 141 citations

Intensive Therapy, Venous Disease, Health Sciences +13